Rexahn Pharmaceuticals Receives U.S. Patent for New Cancer Compounds
Rexahn Pharmaceuticals, Inc. (AMEX: RNN), a leader in innovative therapeutics for life-threatening and life-debilitating diseases, today announced that the U.S. Patent & Trademark Office has issued to the Company U.S. Patent 7,388,014, entitled \"Quinazoline Derivatives and Therapeutic Use Thereof.\"
Patent 7,388,014 covers Rexahn’s anticancer candidate, RX-0183 and related compounds, and are targeted, small molecule quinazoline analogues that inhibit key molecules such as c-Fos and Akt proteins. Akt and c-Fos proteins are cancer cell signaling targets involved in transduction, growth and proliferation.
- Published: 28 July 2008
- Written by Editor